cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
During Bryson's 20-month tenure as Lilly's president and CEO, the company reported its first quarterly loss as a publicly traded company. In 1993, Randall L. Tobias, vice chairman of AT&T Corporation and a Lilly board member, was named Lilly's chairman, president, and CEO, the first president and CEO recruited from outside of the company. In 1994, Lilly separated its medical device division. It also acquired PCS Systems, the largest drug benefits health maintenance organization at the time, for $4 billion. Released in 1996, Zyprexa (Olanzapine) (for schizophrenia and bipolar disorder, as well as off-label uses) (see Illegal marketing of Zyprexa) was the company's best-selling drug through 2010, when the patent expired. In May 1996, the Food and Drug Administration approved gemcitabine (Gemzar) for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiation therapy. Gemzar is also routinely used to treat non-small cell lung cancer. In 1998, the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis. Sidney Taurel, former chief operating officer of Lilly, was named CEO in July 1998 to replace Tobias, who retired. Taurel became chairman of the board in January 1999. Taurel retired as CEO in March 2008, but remained as chairman of the board until 31 December 2008. John C. Lechleiter was elected as Lilly's CEO and president, effective 1 April 2008.
=== Madonna vs Harlot === Tanizaki is known for his use of the tropes of Madonna and Harlot. In speaking with his cousin Takanatsu, Kaname reveals that he is interested in only two types of women: the motherly type and the whore type (bofugata and shoufugata, respectively). What he looks for in a woman oscillates between the two, and the fact that his wife is neither one nor the other, but a mix of both, is largely the impetus behind his waning interest in her. Kaname prefers extremes, which will become more and more apparent as the novel progresses. There is some sort of reconciliation between these two extremes, however, and it is found in the “Eternal Woman” (eien josei), a woman to be worshiped.
Aurélia Nguyen is a French-Vietnamese public health official, and the current Deputy Chief Executive Officer of CEPI (Coalition for Epidemic Preparedness Innovations)[1]. She previously was the managing director of the COVAX Facility at Gavi (formerly Global Alliance for Vaccines and Immunization.). In her role at COVAX, she works on providing COVID-19 vaccines to lower income countries, and tackling issues such as vaccine diplomacy, exports controls, limited supplies and cold-chain logistics.
Sources: en.wikipedia.org
August 19–September 1: The Viet Minh seizes control of Hanoi and much of the former Empire of Vietnam after the surrender of Japan, proclaiming the Democratic Republic of Vietnam and initiating civil conflicts. September 2: Surrender of Japan - The Empire of Japan surrenders unconditionally to the United States, officially ending World War II. General Douglas MacArthur presides over the occupation of Japan, and freezes out Russian and other allied representatives(V-J day). September 5: Igor Gouzenko, a Soviet agent working in the Soviet embassy in Canada, defects and provides proof to the Royal Canadian Mounted Police of a Soviet spy ring operating in Canada and the U.S. The revelations help change perceptions of the Soviet Union from an ally to a foe. October 25: Taiwan is transferred to the Republic of China from Japan. Initially the Chinese public was supportive of the transfer but later becomes less so as the newly appointed governor, General Chen Yi gains a reputation for being corrupt and mismanaging the island. Economic problems also occur as the governor extends the scope of the government monopoly over Taiwan's resources in order to sell these goods to the mainland to help fight the Communist forces. The conditions on the island later contribute to the February 28 incident. November: Iran crisis of 1946 - Stalin refuses to relinquish Soviet-occupied territory in Iran, beginning the Iran Crisis. Two short-lived pro-Soviet states, the Azerbaijan People's Government and the Republic of Mahabad, are formed. November 20: The Nuremberg trials begin.
By the late 1940s, the economic wounds from years of redlining and restrictive covenants hurt the standard of living for many African Americans and minorities living in Detroit. With limited housing opportunities and sky-high rents, those living in "red" neighborhoods like Black Bottom and Paradise Valley often had little financial ability to pay for private apartments or housing repairs. Consequences of close-quarter living were exacerbated by an influx of black immigrants during the Great Migration and World War II. The decaying neighborhoods also developed sanitation problems; garbage pickups were rare, and trash littered the street, accelerating the spread of diseases and enticing pests. Perceptions of "urban blight" and a need for "slum clearance" in these areas were fueled especially by (majority white) Detroit city planners, who classified over two-thirds of housing in Paradise Valley as substandard. Detroit Mayor Edward Jeffries put forth a plan for "urban renewal" in Black Bottom and Paradise Valley neighborhoods in 1944. Utilizing eminent domain laws, the government began taking down buildings in the Black Bottom neighborhood in 1949. Local government officials popularized the push for urban renewal in post-World War II Detroit in conjunction with real estate agents and bank owners, who stood to gain from investment in new buildings and wealthier residents.
Histologic evidence of acantholysis (loss of intercellular connections leading to breaking apart of the skin; lesion) Direct immunofluorescence showing intercellular and basement membrane staining Indirect immunofluorescence staining with rat bladder epithelium
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.